CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma

References

• Shipp M A, Harrington D P, Anderson J R, Armitage J O, Bonnadonna G, Brittinger G, et al. A predictive model for aggressive NHL. The International Non-Hodgin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res 2003; 9: 722–728
   PubMed Web of Science ®Google Scholar
• Schultze J L, Cardoso A A, Freeman G J, Seamon M J, Daley J, Pinkus G S, et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995; 92: 8200–8204
   PubMed Web of Science ®Google Scholar
• Kato K, Cantwell M J, Sharma S, Kipps T J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101: 1133–1141
   PubMed Web of Science ®Google Scholar
• Khanna R, Cooper L, Kienzle N, Moss D J, Burrows S R, Khanna K K. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 1997; 159: 5782–5785
   PubMed Web of Science ®Google Scholar
• Lippman S M, Spier C M, Miller T P, Slymen D J, Rybski J A, Grogan T M. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol 1990; 3: 361–367
   PubMed Web of Science ®Google Scholar
• Stopeck A T, Gessner A, Miller T P, Hersh E M, Johnson C S, Cui H, et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 2000; 6: 3904–3909
   PubMed Web of Science ®Google Scholar
• Rimsza L M, Roberts R A, Miller T P, Unger J M, LeBlanc M, Braziel R M, et al. Loss of MHC class II gene and protein expression in diffuse large B cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival irrespective of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103: 4251–4258
   PubMed Web of Science ®Google Scholar
• Ansell S M, Stenson M, Habermann T M, Jelinek D F, Witzig T E. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001; 19: 720–726
   PubMed Web of Science ®Google Scholar
• Xu Y, Kroft S H, McKenna R W, Aquino D B. Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br J Haematol 2001; 112: 945–949
   PubMed Web of Science ®Google Scholar
• Altman D G. Practical Statistics for Medical Research. Chapman & Hall, London 1991; 394
   Google Scholar
• Sasaki T, Hoshida Y, Xu J X, Tomita Y, Sakane-Ishikawa E, Fujita S, et al. Prognostic significance of CD40 expression in malignant lymphoma developing in rheumatoid arthritis. J Cancer Res Clin Oncol 2005; 131: 797–802
   PubMed Web of Science ®Google Scholar
• Vyth-Dreese F A, Boot H, Dellemijn T A, Majoor D M, Oomen L C, Laman J D, et al. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology 1998; 94: 580–586
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2–17
   PubMed Web of Science ®Google Scholar
• DiSanto J P, Bonnefoy J Y, Gauchat J F, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 1993; 361: 541–543
   PubMed Web of Science ®Google Scholar
• Basso K, Klein U, Niu H, Stolovitzky G A, Tu Y, Califano A, et al. Tracking CD40 signaling during germinal center development. Blood 2004; 104: 4088–4096
   PubMed Web of Science ®Google Scholar
• Ridge J P, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474–478
   PubMed Web of Science ®Google Scholar
• Bennett S R, Carbone F R, Karamalis F, Flavell R A, Miller J F, Heath W R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478–480
   PubMed Web of Science ®Google Scholar
• Schoenberger S P, Toes R E, van der Voort E I, Offringa R, Melief C J. T-cell help for cytotoxic T lymphocytes is mediated by CD40 – CD40L interactions. Nature 1998; 393: 480–483
   PubMed Web of Science ®Google Scholar
• French R R, Taraban V Y, Crowther G R, Rowley T F, Gray J C, Johnson P W, et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007; 109: 4810–4815
   PubMed Web of Science ®Google Scholar
• Ritchie D S, Yang J, Hermans I F, Ronchese F. B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells. Scand J Immunol 2004; 60: 543–551
   PubMed Web of Science ®Google Scholar
• Yang Z Z, Novak A J, Stenson M J, Witzig T E, Ansell S M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639–3646
   PubMed Web of Science ®Google Scholar
• Vonderheide R H. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007; 13: 1083–1088
   PubMed Web of Science ®Google Scholar